Summary
The cytotoxic effects of ketoconazole, an antifungal agent known to have some activity against human prostate cancer, adrenal cancer, and male metastatic breast cancer, were evaluated using colony-growth and clonogenic assays in eight malignant cell lines. The cytotoxicity of ketoconazole showed a dose-and time-dependent pattern, with the following concentrations, inhibiting 90% of the growing colonies (IC90): MCF 7 (human breast cancer) 7.25 μg/ml, T 47 D (human breast cancer) 9.0 μg/ml, MiaPaCa (human pancreatic carcinoma) 10.0 μg/ml, COLO 357 (human pancreatic carcinoma) 9.5 μg/ml, HCT 8 (human colonic adenocarcinoma) 27.1 μg/ml, DU 145 (human prostatic cancer) 40.0 μg/ml, AR 42 J (rat pancreatic carcinoma) 9.0 μg/ml, and L1210 (murine leukemia) 8.6 μg/ml. Since a concentration of 10 μg/ml can be achieved in humans, the use of ketoconazole in human malignancies might be worthy of clinical evaluation.
Similar content being viewed by others
References
Beggs WH, Andrews FA, Sarosi GA (1981) Action of imidazole-containing antifungal drugs. Life Sci 28: 111–118
Buttke TM, Chapman SW (1983) Inhibition by ketoconazole of mitogen-induced DNA synthesis and cholesterol biosynthesis in lymphocytes. Antimicrob Agents Chemother 24: 478–485
Castillo C (1985) Ketoconazole in the treatment of advanced cancer ot the prostate: experience with 14 patients. Rev Med Chil 113: 309–311
Contreras P, Auristella R (1985) Regression of metastatic adrenal carcinoma during palliative ketoconazole treatment. Lancet II: 151–152
Damon LE, Rochlitz CF (1988) Sequence-dependent cytotoxicity between VP16 and fluoropyrimidines (in press)
De Coster R, Beerens D, Dom J, Willemsen G (1984) Endocrinological effects of single daily ketoconazole administration in male beagle dogs. Acta Endocrinol (Copenh) 107: 275–281
De Felice R, Johnson DC, Galgiani JN (1981) Gynecomastia with ketoconazole. Antimicrob Agents Chemother 19: 1073–1074
Dismukes WE (1983) Treatment of systemic mycosis with ketoconazole: Emphasis on toxicity and clinical response in 52 patients. Ann Intern Med 98: 13–20
Feldman LD (1986) Ketoconazole for male metastatic breast cancer. Ann Intern Med 104: 123–124
Heyns W, Drochmans A, van der Scuerren E, Verhoeven G (1985) Endocrine effects of high-dose ketoconazole therapy in advanced prostatic cancer. Acta Endocrino (Copenh) 110: 276–283
Kraemer FB, Pont A (1986) Inhibition of cholesterol synthesis by Ketoconazole. Am J Med 80: 616–622
Pont A (1982) Ketoconazole inhibits adrenal steroid synthesis. Clin Res 30: 99A
Pont A (1984) High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med 144: 2150–2153
Pont A, Goldman ES (1985) Ketoconazole-induced increase in estradiol-testosterone ratio. Arch Intern Med 145: 1429–1431
Pont A, Williams PL (1982) Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med 97: 370–372
Pont A, Williams PL (1982) Ketoconazole blocks testosterone synthesis. Clin Res 30: 32A
Pont A, Williams PL, Azhar S, Reiter R, Bochra C, Smith ER, Stevens DA (1982) Ketoconazole blocks testosterone synthesis. Arch Intern Med 142: 2137–2140
Restrepo A, Stevens DS, Utz JP (1980) First international symposium on ketoconazole. Ref Infect Dis 2: 519–562
Santen RJ, Van den Bossche H, Symoens J, Brugmans J, De Coster R (1983) Site of action of low-dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab 57: 732–736
Schurmeyer T, Nieschlag E (1984) Effect of ketoconazole and other imidazole fungicides on testosterone biosynthesis. Acta Endocrinol (Copenh) 105: 275–280
Sheets JL, Mason JI (1984) Ketoconazole: A potent inhibitor of cytochrome P-450-dependant drug metabolism in rat liver. Drug Metab Dispos 12: 603–606
Trachtenberg J (1984) Ketoconazole therapy in advanced prostatic cancer. J Urol 132: 61–63
Van den Bossche H, Willemsen G, Cools W, Cornelissen F, Lauwers W, Cutsem J (1980) In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother 17: 922–928
Van Tyle JH (1984) Ketoconazole: Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy 4: 343–373
Williams G (1986) Objective response to ketoconazole therapy in patients with relapsed progressive prostatic cancer. Br J Urol 58: 45–51
Author information
Authors and Affiliations
Additional information
This investigation was supported in part by a grant from the German Volkswagen Foundation, Hannover, Federal Republic of Germany and by a gift from Dr Virgil Gianelli, Stockton, California
Rights and permissions
About this article
Cite this article
Rochlitz, C.F., Damon, L.E., Russi, M.B. et al. Cytotoxicity of ketoconazole in malignant cell lines. Cancer Chemother. Pharmacol. 21, 319–322 (1988). https://doi.org/10.1007/BF00264198
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00264198